Floatz logo

Trivalent Influenza Vaccine

Influenza Vaccine

Shanghai Pulmonary Hospital, Shanghai, ChinavaccineDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Influenza Vaccine cohort.

Asset / SponsorPhaseRating
Vaxigrip
Medical University of Warsaw
Phase 4BB
Oseltamivir
The University of Hong Kong
Phase 3BB
Dfn-15
The University of Hong Kong
Phase 3B
Trivalent Baculovirus-Expressed Influenza Ha Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2B
Trivalent Influenza Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2B

View all 9 →

Same molecule, other indications

Trivalent Influenza Vaccine is also rated in:

relapsing-remitting multiple sclerosisDormant
B
Indicative ·
57 / 100
View asset →
influenzaDormant
B
Indicative ·
57 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →